摘要
目的:评价伊曲康唑口服液预防急性白血病(AL)深部真菌感染疗效及安全性。方法:2004年12月～2005年12月我科AL住院高危患者入选研究。治疗组接受伊曲康唑口服液预防性治疗,剂量为200mg,每天2次,持续至粒细胞缺乏(粒缺)恢复或发生发热或其他感染性事件。对照组不接受任何抗真菌药物治疗。结果:143例患者入选研究,其中预防治疗组65例患者,17例(26.2%)出现发热,对照组78例患者,26例(33.3%)出现发热。两组比较,发热事件的发生率无统计学意义(P=0.367)。伊曲康唑口服液的主要不良反应为腹泻(9.2%)。预防治疗组抗真菌治疗总费用为390233元,人均6004元;对照组抗真菌治疗总费用为410200元,人均5259元。预防治疗组的粒缺-真菌治疗终点住院时间短于对照组(P=0.048)。结论:伊曲康唑口服液可安全地应用于AL患者深部真菌感染预防治疗。
Objective To evaluate the efficacy and safety of itraconazole oral solution in preventing the invasive fugal infection （IFI） in patients with acute leukemia. Methods During the period from December 2004 to December 2005, hospitalized acute leukemia patients with high risk of developing IFI were enrolled into this study, receiving either itraeonazole oral solution, 200 mg twice daily （a prevention group）, or standard treatment without anti-fungal therapy （a control group）. The treatment was continued until the recovery of neutropenia or the occurance of febrile events. Results Among 143 patients enrolled, 65 patients received itraconazole therapy. Seventeen patients in the prevention group （26.2%） and 26 patients in the control group （26/78 or 33.3%） developed fever events, with no statistical significance （P=0.367）. The most common adverse event of itraconazole treatment was diarrhea, which occured in 6 patients （9.2%）. The total cost in the prevention group was 390 233 RMB, with 6 004 RMB per capita; while those in the control group were 410 200 RMB and 5 259 RMB per capita, respectively. The length of hospitalization in the prevention group was significantly shorter than that in the control group （17.7 days vs 23.1days, P=0.048）. Conclusions hraconazole oral solution could be safely administrated in the prophylaxis of IFI in acute leukemia patients.
出处
《内科理论与实践》
2007年第1期49-51,共3页
Journal of Internal Medicine Concepts & Practice
关键词
伊曲康唑
预防治疗
高危
真菌感染
Itraconazole
Prophylaxis
High risk
Fungal infection
